One good thing that will force big pharma to use the repatriated earnings to acquire small biotech's is the Treasury stating clearly that "stock buy-back" does NOT constitute a qualified reinvestment. I suspect most big pharmas have very little debt and cannot fully expend the funds on ongoing R&D.... thus, acquisitions will be coming sooner or later.
Market Data 
Markets 
AI
